|
Name |
Pandangolide 1a
|
Molecular Formula | C12H20O5 | |
IUPAC Name* |
(4S,6S,12S)-4,6-dihydroxy-12-methyl-oxacyclododecane-2,5-dione
|
|
SMILES |
C[C@H]1CCCCC[C@@H](C(=O)[C@H](CC(=O)O1)O)O
|
|
InChI |
InChI=1S/C12H20O5/c1-8-5-3-2-4-6-9(13)12(16)10(14)7-11(15)17-8/h8-10,13-14H,2-7H2,1H3/t8-,9-,10-/m0/s1
|
|
InChIKey |
LSLSZASQWJAEHT-GUBZILKMSA-N
|
|
Synonyms |
Pandangolide 1a; (4S,6S,12S)-4,6-dihydroxy-12-methyloxacyclododecane-2,5-dione; CHEBI:59875; Q27126931; (4S,6S,12S)-4,6-dihydroxy-12-methyl-oxacyclododecane-2,5-dione
|
|
CAS | NA | |
PubChem CID | 11687387 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 244.28 | ALogp: | 0.8 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 17 | QED Weighted: | 0.62 |
Caco-2 Permeability: | -4.802 | MDCK Permeability: | 0.00009540 |
Pgp-inhibitor: | 0.242 | Pgp-substrate: | 0.085 |
Human Intestinal Absorption (HIA): | 0.063 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.894 |
Blood-Brain-Barrier Penetration (BBB): | 0.383 | Plasma Protein Binding (PPB): | 30.01% |
Volume Distribution (VD): | 0.348 | Fu: | 64.43% |
CYP1A2-inhibitor: | 0.014 | CYP1A2-substrate: | 0.167 |
CYP2C19-inhibitor: | 0.031 | CYP2C19-substrate: | 0.554 |
CYP2C9-inhibitor: | 0.009 | CYP2C9-substrate: | 0.321 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.128 |
CYP3A4-inhibitor: | 0.007 | CYP3A4-substrate: | 0.161 |
Clearance (CL): | 7.339 | Half-life (T1/2): | 0.73 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.337 |
Drug-inuced Liver Injury (DILI): | 0.301 | AMES Toxicity: | 0.9 |
Rat Oral Acute Toxicity: | 0.106 | Maximum Recommended Daily Dose: | 0.7 |
Skin Sensitization: | 0.629 | Carcinogencity: | 0.101 |
Eye Corrosion: | 0.033 | Eye Irritation: | 0.688 |
Respiratory Toxicity: | 0.7 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002164 | 1.000 | D07GRH | 0.294 | ||||
ENC002063 | 0.661 | D04URO | 0.284 | ||||
ENC002048 | 0.586 | D0N4PZ | 0.257 | ||||
ENC002735 | 0.524 | D0P6VV | 0.244 | ||||
ENC001414 | 0.524 | D03DVJ | 0.242 | ||||
ENC002098 | 0.500 | D0L9ZR | 0.228 | ||||
ENC004419 | 0.500 | D0C7JF | 0.227 | ||||
ENC002200 | 0.500 | D0G6AB | 0.227 | ||||
ENC003404 | 0.477 | D04VIS | 0.226 | ||||
ENC004377 | 0.477 | D04JPJ | 0.222 |